CNA Diagnostics Inc.
CNA DIAGNOSTICS INC. (CNAD) is a molecular diagnostics company specializing in the development and licensing of genome-specific biomarkers to a global diagnostics market. The technology will detect multiple human and animal diseases long before clinical signs provide evidence that a disease or infection exists. The CNAD team is focused in the short-term on the initial commercialization of its first two bovine tests and a diagnostic test for sepsis, which is the body’s extreme response to an infection. It is life-threatening, and without immediate treatment, sepsis can rapidly cause tissue damage, organ failure, and death.
Unique to the CNAD diagnostics platform is the bioinformatics pipeline, which was built over 7.5 years at the University of Calgary. Importantly, the technology delivers a repeatable and scalable process for biomarker development. This novel bioinformatics system allows CNAD to match DNA sequences and phenotypic information with earlier stages of disease progress providing the subsequent identification of biomarkers related to the disease state of the target genome, be it human or animal.
The world of human and veterinarian medicine knows that early diagnosis of any disease condition is the key to saving life through early treatment. Further benefits of this proprietary technology grow by reducing the misuse of antibiotics, restraining antimicrobial resistance as our most serious health threat of the next century. The company’s current intellectual property portfolio, which is in various stages of development encompasses eight diseases in total: four in human, three in production livestock and one in companion animals. This biomarker discovery can provide a new pathway to a potentially disruptive technology to change the gold standard in diagnostic medicine.